Results 91 to 100 of about 2,479 (207)

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 672-687, March 2026.
Abstract Background The transient receptor potential melastatin 3 (TRPM3) ion channel has been implicated in sensory modulation and pain transmission and may contribute to migraine pathophysiology through calcitonin gene‐related peptide (CGRP) release in the trigeminovascular system. This study aimed to investigate TRPM3 activation and its role in CGRP
Philip V. Reducha, Lukas K. S. Nielsen, Mette N. Jensen, Jacob C. A. Edvinsson, Spyridoula Kazantzi, Sofia L. Wæver, Tanja Lylloff, Connar S. J. Westgate, Lars Edvinsson, Kristian A. Haanes   +9 more
wiley   +1 more source

Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis [PDF]

, 2023
BACKGROUND: Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective.
Aksentyte, A, Brown, A, Cooklin, A, Davies, N, Duncan, C, Grove, A, Madan, J, Matharu, M, Mistry, H, Naghdi, S, Rees, S, Underwood, M   +11 more
core  

Advancing the Tendinopathy Triad: Comment on “Tendinopathy: The Interplay Between Mechanical Stress, Inflammation, and Vascularity”

Advanced Science, Volume 13, Issue 9, 13 February 2026.
Abstract Building upon the integrative framework of tendinopathy proposed by Gehwolf et al.—which elegantly connects mechanical stress, inflammation, and vascularity—this commentary extends the discussion by introducing novel mechanistic insights and future research directions that move beyond the established triad. A paradigm shift is proposed ...
DuJiang Yang, Jiexiang Yang, Shuang Wang, GuoYou Wang   +3 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Predicting Pharmacological Treatment Response in Migraine Using AI/ML: A Scoping Review of the Evidence and Future Directions

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT The treatment of migraine is hampered by inter‐individual variability, leading to an inefficient “trial and error” approach. Artificial intelligence (AI) and machine learning (ML) offer a path towards precision medicine by predicting therapeutic outcomes.
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

COMPARISON OF EFFICACY AND SAFETY OF NEWER DRUGS APPROVED FOR THE TREATMENT OF MIGRAINE DISORDER: A REVIEW [PDF]

, 2020
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms.
CHEW, TENG TENG, GOVINDARAJAN, ARULKUMARAN, KRISHNASAMY, KARTHIKAYINI, LAU, NATALIE JIA XIN, MEETOOA, BIBI MUNIIRAH UMMEH HAANI, NG, ELAINE, ONG, MICHELLA, ROSMAN, AIDIL NATASHA, SHANMUGASUNDARAM, AKILA, SHAPHERI, AINAA DIYANA, SIVANANDY, PALANISAMY, YEONG, MICHELLE ZI YIN   +11 more
core   +1 more source

Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study [PDF]

Background and PurposeFremanezumab, a monoclonal antibody targeting the calcitonin gene-related peptide for migraine prevention, is available in monthly (225 mg) and quarterly (675 mg) doses. Previous studies showed efficacy and safety for both regimens,
Altamura, Claudia, Cetta, Ilaria, Cevoli, Sabina, Colombo, Bruno, Favoni, Valentina, Filippi, Massimo, Genovese, Federica, Guerrieri, Simone, Messina, Roberta, Vernieri, Fabrizio, Zanandrea, Laura   +10 more
core   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies [PDF]

, 2020
Aim of study. To analyse Polish neurologists’ familiarity with the diagnostic criteria for migraine, and how their methods of management of migraine work in daily practice.Clinical rationale for study.
Domitrz, Izabela, Kozubski, Wojciech, Lipa, Aurelia, Rożniecki, Jacek, Stępień, Adam   +4 more
core   +2 more sources

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Neurology and Therapy
Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and  3 treatment failures and various comorbidities.
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group   +32 more
doaj   +1 more source